Phase I Dose Escalation of Velcade (Bortezomib) Daily Dose in Patients With Advances or Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 02 Nov 2017
Price : $35 *
At a glance
- Drugs Bortezomib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms VELDAY
- 02 Nov 2017 Results assessing safety, pharmacokinetics effect, biological effects and early clinical evaluation, published in the Investigational New Drugs.
- 30 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 22 Aug 2014 New trial record